Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia

[1]  David A. Brafman,et al.  APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer’s disease patient iPSC-derived cerebral organoids , 2020, Nature Communications.

[2]  C. Cotman,et al.  Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease , 2020, Nature Communications.

[3]  Ian F. Harrison,et al.  Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model , 2020, Brain : a journal of neurology.

[4]  Terrance T. Kummer,et al.  Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. , 2020, The Journal of clinical investigation.

[5]  Jamie L. Marshall,et al.  Disease-associated astrocytes in Alzheimer’s disease and aging , 2020, Nature Neuroscience.

[6]  N. Neff,et al.  Molecular characterization of selectively vulnerable neurons in Alzheimer’s Disease , 2020, Nature Neuroscience.

[7]  A. Fagan,et al.  APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline , 2020, Nature.

[8]  Jesse A. Brown,et al.  Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET , 2020, Science Translational Medicine.

[9]  Steve Lianoglou,et al.  TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge , 2019, Neuron.

[10]  Muhammad Naveed Iqbal Qureshi,et al.  Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. , 2019, JAMA neurology.

[11]  Maxim N. Artyomov,et al.  Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and - independent cellular responses in Alzheimer’s disease , 2019, Nature Medicine.

[12]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[13]  D. Holtzman,et al.  Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model , 2019, Molecular Neurodegeneration.

[14]  Bin Zhang,et al.  Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation , 2019, bioRxiv.

[15]  D. Holtzman,et al.  Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model , 2019, The Journal of experimental medicine.

[16]  Paul E. Gilbert,et al.  APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia , 2019, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[17]  P. Ivanov,et al.  Stress granules and neurodegeneration , 2019, Nature Reviews Neuroscience.

[18]  Tobias C. Wood,et al.  CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice , 2019, Brain : a journal of neurology.

[19]  Melanie A. Huntley,et al.  Complement C3 Is Activated in Human AD Brain and Is Required for Neurodegeneration in Mouse Models of Amyloidosis and Tauopathy. , 2019, Cell reports.

[20]  B. Ueberheide,et al.  PHOSPHORYLATED TAU INTERACTOME IN THE HUMAN ALZHEIMER’S DISEASE BRAIN , 2019, Alzheimer's & Dementia.

[21]  Paul J. Hoffman,et al.  Comprehensive Integration of Single-Cell Data , 2018, Cell.

[22]  Nicola Thrupp,et al.  The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques , 2019, Cell reports.

[23]  R. Satija,et al.  Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression , 2019, Genome Biology.

[24]  B. Miller,et al.  Alzheimer’s disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation , 2019, bioRxiv.

[25]  D. Bennett,et al.  Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease , 2019, Alzheimer's & Dementia.

[26]  Melanie A. Huntley,et al.  Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies , 2018, Neuron.

[27]  Nicholas E. Propson,et al.  Complement C3aR Inactivation Attenuates Tau Pathology and Reverses an Immune Network Deregulated in Tauopathy Models and Alzheimer’s Disease , 2018, Neuron.

[28]  D. Holtzman,et al.  Loss of TREM2 function increases amyloid seeding but reduces plaque associated ApoE , 2018, Nature Neuroscience.

[29]  L. Petrucelli,et al.  APOE ε2 is associated with increased tau pathology in primary tauopathy , 2018, Nature Communications.

[30]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[31]  D. Baker,et al.  Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline , 2018, Nature.

[32]  D. Holtzman,et al.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight , 2018, Nature Reviews Immunology.

[33]  Liqin Zhao,et al.  Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention , 2018, The Journal of Neuroscience.

[34]  Matthew D. Young,et al.  SoupX removes ambient RNA contamination from droplet-based single-cell RNA sequencing data , 2018, bioRxiv.

[35]  D. Holtzman,et al.  ApoE facilitates the microglial response to amyloid plaque pathology , 2018, The Journal of experimental medicine.

[36]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[37]  I. Vida,et al.  The RNA-binding protein ARPP21 controls dendritic branching by functionally opposing the miRNA it hosts , 2018, Nature Communications.

[38]  G. Bu,et al.  ApoE4 Accelerates Early Seeding of Amyloid Pathology , 2017, Neuron.

[39]  D. Holtzman,et al.  Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis , 2017, Neuron.

[40]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[41]  W. M. van der Flier,et al.  Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer’s Disease , 2017, Journal of Alzheimer's disease : JAD.

[42]  Hu Li,et al.  Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo , 2017, Nature Neuroscience.

[43]  G. Bu,et al.  Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes , 2017, Neuron.

[44]  A. Fagan,et al.  ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy , 2017, Nature.

[45]  Markus Glatzel,et al.  The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.

[46]  S. Younkin,et al.  APOE &egr;4/&egr;4 diminishes neurotrophic function of human iPSC-derived astrocytes , 2017, Human molecular genetics.

[47]  I. Amit,et al.  A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.

[48]  Timothy A. Miller,et al.  Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy , 2017, Science Translational Medicine.

[49]  Peyman Golshani,et al.  New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo , 2016, Neuron.

[50]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[51]  D. Holtzman,et al.  Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models , 2015, Acta neuropathologica communications.

[52]  S. Younkin,et al.  Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)* , 2015, The Journal of Biological Chemistry.

[53]  N. Pochet,et al.  Targeting miR‐155 restores abnormal microglia and attenuates disease in SOD1 mice , 2015, Annals of neurology.

[54]  J. Noraberg,et al.  Zbtb20 defines a hippocampal neuronal identity through direct repression of genes that control projection neuron development in the isocortex. , 2014, Cerebral cortex.

[55]  S. Gygi,et al.  Identification of a Unique TGF-β Dependent Molecular and Functional Signature in Microglia , 2013, Nature Neuroscience.

[56]  Chadwick M. Hales,et al.  U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.

[57]  B. Zlokovic.  Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. , 2013, JAMA neurology.

[58]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[59]  Guojun Bu,et al.  Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[60]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[61]  J. Herz,et al.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.

[62]  John D. Lambris,et al.  The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.

[63]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[64]  W. Gan,et al.  The P2Y12 receptor regulates microglial activation by extracellular nucleotides , 2006, Nature Neuroscience.

[65]  S Minoshima,et al.  Cerebral glucose metabolism in patients with AD and different APOE genotypes , 2005, Neurology.

[66]  Xianlin Han,et al.  ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* , 2004, Journal of Biological Chemistry.

[67]  L. Bernier,et al.  Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain* , 2004, Journal of Biological Chemistry.

[68]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[69]  Thomas Arendt,et al.  Plastic Neuronal Remodeling Is Impaired in Patients with Alzheimer’s Disease Carrying Apolipoprotein ε4 Allele , 1997, The Journal of Neuroscience.

[70]  P. Lopresti,et al.  Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[71]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. Mahley,et al.  Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. , 1987, Biochimica et biophysica acta.